Search

Your search keyword '"Laura Scelsi"' showing total 2 results
Start Over Author "Laura Scelsi" Publisher european respiratory society (ers)
2 results on '"Laura Scelsi"'

1. Magnetic resonance imaging of pulmonary arterial compliance after pulmonary endarterectomy

Author

Adele Valentini, Anna Celentano, Stefania Guida, Robert Naeije, Maurizio Pin, Stefano Ghio, Gabriele Crimi, Claudia Raineri, Laura Scelsi, Andrea Maria D'Armini, Luigi Oltrona Visconti, and Annalisa Turco

Subjects
Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Hypertension, Pulmonary, Endarterectomy, Pulmonary Artery, Pulmonary endarterectomy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine.artery, medicine, Humans, 030212 general & internal medicine, skin and connective tissue diseases, Lung Compliance, Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, Magnetic resonance imaging, Middle Aged, Exercise capacity, Magnetic Resonance Imaging, Compliance (physiology), 030228 respiratory system, Catheterization, Swan-Ganz, Pulmonary artery, Cardiology, Female, sense organs, Pulmonary Embolism, business
Abstract

In CTEPH patients who have undergone pulmonary endarterectomy, exercise capacity is better associated with changes in invasively measured pulmonary arterial compliance than with changes in magnetic resonance imaging of pulmonary artery stiffnesshttp://bit.ly/30DAWUj

Published
2020

2. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors

Author

Pablo Colorado, Dennis Busse, Stephan Rosenkranz, Christian Meier, Raymond L. Benza, Hossein Ardeschir Ghofrani, Gérald Simonneau, James R. Klinger, Laura Scelsi, Carmine Dario Vizza, Mikyung Chang, David Langleben, Robert Naeije, Paul A. Corris, Pavel Jansa, Marius M. Hoeper, and Ekkehard Grünig

Subjects
Adult, Endothelin Receptor Antagonists, Male, Pulmonary and Respiratory Medicine, Pediatrics, medicine.medical_specialty, Adolescent, Hypertension, Pulmonary, Cardiac index, Walk Test, 030204 cardiovascular system & hematology, World Health Organization, Severity of Illness Index, Riociguat, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Physiologie générale, Respite care, Internal medicine, Natriuretic Peptide, Brain, Humans, Medicine, Prospective Studies, Adverse effect, Prospective cohort study, Antihypertensive Agents, Aged, business.industry, Middle Aged, Phosphodiesterase 5 Inhibitors, Brain natriuretic peptide, pulmonary arterial hypertension, treatment, PDE-5 inhibitor, riociguat, Peptide Fragments, Europe, Pyrimidines, Treatment Outcome, medicine.anatomical_structure, 030228 respiratory system, Concomitant, North America, Vascular resistance, Pyrazoles, Female, Vascular Resistance, business, medicine.drug
Abstract

A proportion of pulmonary arterial hypertension (PAH) patients do not reach treatment goals with phosphodiesterase-5 inhibitors (PDE5i). RESPITE investigated the safety, feasibility and benefit of switching from PDE5i to riociguat in these patients. RESPITE was a 24-week, open-label, multicentre, uncontrolled study. Patients in World Health Organization (WHO) functional class (FC) III, with 6-min walking distance (6MWD) 165-440 m, cardiac index 400 dyn s cm-5 underwent a 1-3 day PDE5i treatmentfree period before receiving riociguat adjusted up to 2.5 mg maximum t.i.d. Exploratory end-points included change in 6MWD, WHO FC, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and safety. Of 61 patients enrolled, 51 (84%) completed RESPITE. 50 (82%) were receiving concomitant endothelin receptor antagonists. At week 24, mean±SD 6MWD had increased by 31±63 m, NT-proBNP decreased by 347±1235 pg mL-1 and WHO FC improved in 28 patients (54%). 32 patients (52%) experienced study drug-related adverse events and 10 (16%) experienced serious adverse events (2 (3%) study drug-related, none during the PDE5i treatment-free period). Six patients (10%) experienced clinical worsening, including death in two (not study drug-related). In conclusion, selected patients with PAH may benefit from switching from PDE5i to riociguat, but this strategy needs to be further studied., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results